Cable Hill Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Cable Hill Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-500	Closed	-$7K	–	915
2018 Q1	$7K	Buy	+500	New	+$8.15K	﹤0.01%	585

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Cable Hill Partners's RCKT Position: Q2 2018 in Review

Cable Hill Partners sold out of Rocket Pharmaceuticals (RCKT) in Q2 2018, closing a stake of 500 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in RCKT in Q1 2018 and held it in 1 quarter. The position peaked at $7K in Q1 2018. 76 funds tracked by Wall St. Rank hold RCKT as of Q2 2018.

Cable Hill Partners reported no remaining Rocket Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Cable Hill Partners sold 500 Rocket Pharmaceuticals shares in Q2 2018, an estimated $7K.
Cable Hill Partners first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Cable Hill Partners's Rocket Pharmaceuticals position peaked at $7K in Q1 2018.
76 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2018.

Based on Cable Hill Partners's 13F filing for Q2 2018, filed 3 Aug 2018.